Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
SHANGHAI PECHEM
00338
5
SINOPEC CORP
00386
HK Stock MarketDetailed Quotes
TEDA BIOMEDICAL (08189)
- 0.199
- -0.001-0.50%
Market Closed May 15 13:29 CST
424.65MMarket Cap-4.23P/E (TTM)
0.205High0.184Low65.00KVolume0.184Open0.200Prev Close12.93KTurnover0.01%Turnover RatioLossP/E (Static)2.13BShares0.54052wk High33.17P/B285.84MFloat Cap0.18452wk Low--Dividend TTM1.44BShs Float1.950Historical High--Dividend LFY10.50%Range %0.058Historical Low0.199Avg Price5000Lot Size--Div Yield TTM--Div Yield LFY
TEDA BIOMEDICAL (08189) Income Statement
All
YOY
| (FY)Dec 31, 2025 | (Q6)Jun 30, 2025 | (FY)Dec 31, 2024 | (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 35.67%522.97M | 7.01%226.41M | -3.14%385.48M | 13.80%211.57M | -1.42%398M | 0.08%305.23M | -9.40%185.92M | -3.11%86.42M | -15.25%403.73M | -14.61%304.97M |
| Operating income | 35.67%522.97M | 7.01%226.41M | -3.14%385.48M | 13.80%211.57M | -1.42%398M | 0.08%305.23M | -9.40%185.92M | -3.11%86.42M | -15.25%403.73M | -14.61%304.97M |
| Cost of sales | -33.41%-487.29M | -6.58%-212.59M | 3.02%-365.26M | -11.38%-199.45M | 3.16%-376.63M | 0.02%-293.73M | 8.10%-179.07M | 0.40%-83.37M | 9.72%-388.91M | 7.76%-293.78M |
| Operating expenses | -33.41%-487.29M | -6.58%-212.59M | 3.02%-365.26M | -11.38%-199.45M | 3.16%-376.63M | 0.02%-293.73M | 8.10%-179.07M | 0.40%-83.37M | 9.72%-388.91M | 7.76%-293.78M |
| Gross profit | 76.41%35.67M | 14.07%13.82M | -5.35%20.22M | 76.90%12.12M | 44.15%21.37M | 2.79%11.5M | -33.96%6.85M | -44.40%3.05M | -67.50%14.82M | -71.03%11.19M |
| Selling expenses | 33.62%-9.24M | 43.85%-3.96M | -71.85%-13.92M | -33.65%-7.05M | 22.96%-8.1M | 25.74%-6.96M | 35.00%-5.28M | 28.86%-3.03M | 39.17%-10.52M | 45.01%-9.37M |
| Administrative expenses | -12.98%-22.98M | ---- | 6.72%-20.34M | ---- | 3.93%-21.8M | ---- | ---- | ---- | 27.87%-22.7M | ---- |
| Research and development expenses | -275.69%-4.14M | -93.37%-16.55M | 16.46%-1.1M | 37.85%-8.56M | -16.09%-1.32M | 4.17%-21.54M | -12.51%-13.77M | -3.66%-6.86M | 67.52%-1.14M | -19.72%-22.48M |
| Profit from asset sales | ---8.22M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --5.91M | ---- |
| Impairment and provision | -697.55%-107.73M | ---- | -20.77%-13.51M | ---- | -115.00%-11.18M | ---- | ---- | ---- | 86.25%-5.2M | ---- |
| -Impairment of property, machinery and equipment | -678.01%-18.74M | ---- | ---2.41M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| -Other impairment is provision | -701.79%-88.99M | ---- | 0.77%-11.1M | ---- | -115.00%-11.18M | ---- | ---- | ---- | 83.96%-5.2M | ---- |
| Special items of operating profit | 250.47%7.49M | 569.34%235.59K | -135.04%-4.98M | 87.93%-50.2K | 1,120.52%14.2M | -116.09%-467.57K | -261.17%-415.76K | -401.43%-80.09K | -71.75%1.16M | 387.72%2.91M |
| Operating profit | -224.58%-109.14M | -81.99%-6.46M | -391.64%-33.63M | 71.89%-3.55M | 61.26%-6.84M | 1.61%-17.47M | -29.65%-12.62M | -28.98%-6.92M | 56.27%-17.65M | -620.45%-17.75M |
| Financing cost | 17.29%-3.79M | 0.19%-1.97M | 11.44%-4.58M | -29.99%-1.98M | 19.19%-5.17M | 38.10%-2.54M | 54.32%-1.52M | -5.24%-781.54K | -17.09%-6.4M | -189.21%-4.1M |
| Share of profits of associates | ---3.44K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Earning before tax | -195.59%-112.94M | -52.57%-8.43M | -218.06%-38.21M | 60.92%-5.53M | 50.06%-12.01M | 8.46%-20M | -8.24%-14.14M | -26.10%-7.71M | 46.35%-24.06M | -1,196.40%-21.85M |
| Tax | -375.21%-609.1K | ---- | -78.80%221.32K | ---- | 105.86%1.04M | 128.30%41.39K | 128.30%41.39K | ---724 | 827.00%507.1K | -278.21%-146.28K |
| After-tax profit from continuing operations | -198.92%-113.54M | -52.57%-8.43M | -246.31%-37.99M | 60.81%-5.53M | 53.42%-10.97M | 9.26%-19.96M | -6.73%-14.1M | -26.11%-7.71M | 47.42%-23.55M | -1,160.09%-22M |
| After-tax profit from non-continuing business | ---- | ---- | 132.95%1.85M | ---- | -129.28%-5.6M | ---- | ---- | ---- | ---2.44M | ---- |
| Special items of earning after tax | ---- | ---- | 132.95%1.85M | ---- | -129.28%-5.6M | ---- | ---- | ---- | ---2.44M | ---- |
| Earning after tax | -214.18%-113.54M | -52.57%-8.43M | -118.10%-36.14M | 60.81%-5.53M | 36.25%-16.57M | 9.26%-19.96M | -6.73%-14.1M | -26.11%-7.71M | 41.96%-25.99M | -1,160.09%-22M |
| Minority shareholders should account for profits from continuing business | -172.56%-22.72M | ---- | -332.28%-8.34M | ---- | 145.81%3.59M | ---- | ---- | ---- | --1.46M | ---- |
| Minority profit | -172.56%-22.72M | -42.91%-2M | -332.28%-8.34M | 50.77%-1.4M | 145.81%3.59M | -617.87%-2.67M | -7,358.70%-2.85M | -2,595.50%-1.83M | 157.73%1.46M | -247.70%-371.67K |
| Shareholders should account for profits from continuing business | -206.33%-90.82M | ---- | -103.66%-29.65M | ---- | 41.79%-14.56M | ---- | ---- | ---- | ---25.01M | ---- |
| Shareholders should account for profits from non-continuing business | ---- | ---- | 132.95%1.85M | ---- | -129.28%-5.6M | ---- | ---- | ---- | ---2.44M | ---- |
| Special items of profit attributable to shareholders | ---- | ---4 | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Adjustment items of profit attributable to shareholders | ---- | --2 | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Profit attributable to shareholders | -226.67%-90.82M | -55.86%-6.43M | -37.91%-27.8M | 63.35%-4.12M | 26.56%-20.16M | 20.03%-17.29M | 15.08%-11.25M | 2.76%-5.88M | 35.03%-27.45M | -1,286.00%-21.63M |
| Basic earnings per share | -199.32%-0.0437 | -45.45%-0.0032 | -37.74%-0.0146 | 62.71%-0.0022 | 26.90%-0.0106 | 20.18%-0.0091 | 15.71%-0.0059 | 3.13%-0.0031 | 34.98%-0.0145 | -1,240.00%-0.0114 |
| Diluted earnings per share | -199.32%-0.0437 | -37.74%-0.0146 | 26.90%-0.0106 | -0.0145 | ||||||
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
| Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | -- | -- | Unqualified Opinion | -- |
| Auditor | Fan Chen Accounting Firm Limited | -- | Fan Chen Accounting Firm Limited | -- | Fan Chen Accounting Firm Limited | -- | -- | -- | Fan Chen Accounting Firm Limited | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Market Insights
Hot Topics Hot Topics
China and the US begin implementing the Kuala Lumpur economic and trade consultation consensus.
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome
牛牛課堂
Oct 13, 2025 18:05
[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?
Food流油
Apr 14, 2025 15:43
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"